QIAGEN N.V. has announced a significant expansion of its cancer genomic profiling portfolio with new products and partnership updates that will be showcased at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25-30.
The Netherlands-based global biotechnology company is introducing new QIAseq panels designed for comprehensive genomic profiling (CGP) that can analyze over 700 genes, representing a major advancement for cancer research and precision medicine applications.
"The launch of the new QIAseq panels represents a significant step forward in enabling researchers to gain deeper, more accurate insights into cancer biology and biomarker discovery along the complete workflow," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN.
Enhanced Cancer Genomic Profiling Capabilities
The expanded QIAseq xHYB CGP portfolio offers a highly curated solution for multimodal cancer genomic profiling, featuring both DNA and RNA panels that capture critical genomic regions. The system is designed to leverage actionable variants sourced from QIAGEN's Human Somatic Mutation Database (HSMD).
At AACR 2025, QIAGEN will highlight these capabilities during a Spotlight Theater presentation featuring Dr. Christopher Reynolds of Myriad Genetics. Dr. Reynolds will present findings from a proof-of-concept study that assessed the panel's performance in variant detection using matched tumor/plasma samples from Stage III/IV prostate and ovarian cancer patients.
The company is also introducing the QIAcuity RCL Quant Kit and new QIAcuity CGT digital PCR (dPCR) assays to support quality control in cell and gene therapy applications, particularly for lentivirus-based technologies used in manufacturing CAR-T therapies. These tools are designed to reliably detect critical quality attributes in biotherapeutics, ensuring therapy safety and efficacy.
Strategic Partnerships Advancing Precision Oncology
QIAGEN is strengthening its partnership with Element Biosciences by integrating the new QIAseq xHYB CGP Panels with Element's AVITI platform and Trinity workflow. This collaboration, expected to be implemented by late 2025, aims to make cancer genomic profiling faster, more cost-effective, and easier to perform by reducing hands-on time and equipment requirements.
In another key partnership development, QIAGEN and Myriad Genetics are collaborating on a sequencing-based homologous recombination deficiency (HRD) assay planned for global launch in 2025 (excluding Japan). This assay is designed to provide deeper molecular insights into DNA repair deficiencies, enhancing researchers' ability to investigate homologous recombination mechanisms and optimize treatment strategies.
Democratizing Access to Genomic Data
In a move to support the broader research community, QIAGEN is introducing HSMD Research, a free, limited version of its Human Somatic Mutation Database. This resource will provide academic researchers with curated insights on 25 key genes involved in solid tumors and blood cancers, including gene annotations, variant distributions, functional impacts, and clinical significance.
"Our new QIAcuity digital PCR kit and assays support pharma companies in developing safe and effective biotherapeutics also for cancer patients. We are moving ahead in supporting scientists and clinicians in advancing cancer research and precision medicine," Sood added.
Market Impact and Future Directions
As a leading provider of Sample to Insight solutions, QIAGEN serves over 500,000 customers globally in Life Sciences and Molecular Diagnostics. These new developments represent significant advancements in the company's oncology portfolio, potentially accelerating cancer research and improving clinical applications.
The integration of advanced genomic profiling tools with bioinformatics capabilities through QIAGEN Digital Insights creates a comprehensive ecosystem for cancer research, from sample processing to data interpretation. This holistic approach addresses a critical need in the field for more efficient and accurate cancer genomic analysis.
Researchers and clinicians interested in learning more about these innovations can visit QIAGEN at booth #2620 at the AACR Annual Meeting 2025, where the company will host featured talks, poster presentations, and product demonstrations.
